Stockscreener 앱 받기
153.87
3.11%
4.64
전일 마감가:
$149.23
열려 있는:
$150.4
하루 거래량:
1.58M
Relative Volume:
0.53
시가총액:
$32.71B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-21.75
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
+3.11%
1개월 성능:
+5.59%
6개월 성능:
+94.97%
1년 성능:
+274.29%
1일 변동 폭
$149.67
$154.74
1주일 범위
$141.44
$154.74
52주 변동 폭
$34.00
$166.50
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance
Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan
Can Revolution Medicines Be a Game-Changer Stock? - Yahoo Finance
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus
Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com
Tango shares surge on early pancreatic cancer combination data - The Pharma Letter
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unlocking a 24.86% Upside Amidst Biotech Breakthroughs - DirectorsTalk Interviews
Total equity of Revolution Medicines, Inc. – XETR:42Z - TradingView
Debt to assets ratio of Revolution Medicines, Inc. – XETR:42Z - TradingView
ETFs Investing in Revolution Medicines, Inc. Stocks - TradingView
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position - Investing.com
Revolution Medicines (RVMD) Drops 4% as Biotech Sector Faces Renewed PressureTrading Ideas - newsline.com
Revolution Medicines in the spotlight for earnings post-trial win By Investing.com - Investing.com Nigeria
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec - Endpoints News
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Revolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stock - MSN
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. - The Motley Fool
Redwood City company develops pill to treat pancreatic cancer, and trial results are promising - NBC Bay Area
What RevMed’s pancreatic cancer drug meant for one patient - statnews.com
Assessing Revolution Medicines (RVMD) Valuation After Positive Daraxonrasib Phase 3 Results At ASCO 2026 - Yahoo Finance
For pancreatic cancer patients, an exciting drug can feel out of reach - statnews.com
Does Revolution Medicines’ pancreatic cancer drug have even greater potential? - statnews.com
Revolution Medicines in the spotlight for earnings post-trial win - Investing.com
Revolution Medicines reports phase 3 win in pancreatic cancer - MSN
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer TreatmentSlideshow (NASDAQ:RVMD) 2026-06-03 - Seeking Alpha
Uprising in pancreatic space more than Revolution - BioWorld News
ASCO’s biggest winners showcased a new era of cancer innovation - BioSpace
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck - BioSpace
'It's still working': More are living with cancer as era of targeted drugs takes hold - marketscreener.com
Video New results from clinical trial of 'groundbreaking' pancreatic cancer treatmentABC News - ABC News - Breaking News, Latest News and Videos
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation (RVMD) - Seeking Alpha
Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says - Moomoo
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $165 to $215 - Moomoo
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD) - The Globe and Mail
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.26%
1.62%
자본화:
|
볼륨(24시간):